Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare's platform combines a proprietary, high-throughput, CRISPR-enabled gene editing target discovery method with high-resolution protein crystallography, computational biology and clinical informatics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/22/17 | $68,000,000 | Series A |
BDC Capital Healthcare Venture Fund Celgene Corporation Fonds de solidarite FTQ MPM Capital  Versant Ventures | undisclosed |
| 09/05/19 | $82,500,000 | Series B |
BDC Capital Healthcare Venture Fund BVF Partners Cowen Healthcare Investments Fonds de solidarite FTQ Logos Capital MPM Capital OrbiMed US Redmile Group Versant Ventures | undisclosed |
